Please login to the form below

Not currently logged in
Email:
Password:

Sativex

This page shows the latest Sativex news and features for those working in and with pharma, biotech and healthcare.

Medical cannabis now available on prescription, for some

Medical cannabis now available on prescription, for some

It already has approval for an oral spray product called Sativex in the UK and other European markets as a treatment for spasticity associated with MS, but this product isn’t

Latest news

  • US approval for first ever cannabis-based medicine US approval for first ever cannabis-based medicine

    The company’s first CBD product was Sativex, first approved over a decade ago, but Epidiolex has built up a more compelling evidence base in these hard-to-treat conditions.

  • GW ascendant as epilepsy drug clears phase III trial GW ascendant as epilepsy drug clears phase III trial

    GW already makes fees and royalty revenues from cannabinoid-based drug called Sativex for moderate to severe spasticity in multiple sclerosis patients who have not responded adequately to other anti-spasticity

  • NICE denies two drugs in new MS guidance NICE denies two drugs in new MS guidance

    process”. Sativex. Sativex is licensed to treat moderate to severe spasticity in MS patients who have not responded adequately to other anti-spasticity medication. ... conduct a full technology appraisal of Sativex, meaning a more “thorough and

  • Cancer pain: opioids set to dominate Cancer pain: opioids set to dominate

    Phase III: opioid agonists. GW Pharmaceuticals has developed a buccal spray known as nabiximols or Sativex, which comprises delta-9-tetrahydrocannabinol (27mg/mL) and cannabidiol (25mg/mL), as an analgesic agent

  • Langland steals the pharma show at first Lions Health Langland steals the pharma show at first Lions Health

    Langland's advertisement for Bayer's Sativex - a winner at the Lions Health awards. ... Stealing the show in this year's pharma category was Langland, which picked up a trio of gold awards for its work on Bayer's multiple sclerosis spasticity brand

More from news
Approximately 3 fully matching, plus 57 partially matching documents found.

Latest Intelligence

  • Death by Numbers Death by Numbers

    Not so. Take the example of this campaign for Sativex, a drug used in the treatment of Multiple Sclerosis. ... The obvious solution to the brief was an ingredient story - Sativex is derived from cannabis.

  • Interview: Jorge Gallardo, Almirall Interview: Jorge Gallardo, Almirall

    Also in 2011, we have launched Sativex,  an oral spray for spasticity in multiple sclerosis, which will be deployed in Europe soon.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • GW hires Pfizer’s Kenneth Sommerville GW hires Pfizer’s Kenneth Sommerville

    GW's research is focused on the development of cannabinoids. This includes Sativex, which became the world's first plant-derived cannabinoid prescription drug when it was approved for multiple sclerosis ... This is an exciting time to be joining GW, with

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics